EPILEPSY RESEARCH is a distinguished journal published by Elsevier, focusing on the dynamic field of neurology with a specific emphasis on epilepsy and related neurological disorders. Since its inception in 1987, the journal has become a vital platform for disseminating cutting-edge research, contributing significantly to the understanding of epileptic conditions and their clinical implications. With an impactful presence in the academic community, EPILEPSY RESEARCH currently holds a 2023 Q2 ranking in both the Neurology and Clinical Neurology categories, reflecting its commitment to high-quality, peer-reviewed content. The journal is indexed in SCOPUS, Ranking #173/400 in Clinical Neurology and #91/192 in Neuroscience, ensuring widespread visibility and academic engagement. Although not an open access publication, it provides critical insights, findings, and reviews that are essential for researchers, clinicians, and students alike, fostering advancements in epilepsy research and treatment. For any inquiries, the journal is based at Radarweg 29, 1043 NX Amsterdam, Netherlands.

EPILEPSIA is a premier academic journal published by Wiley, with a storied history dating back to 1909, making it a cornerstone in the field of epilepsy research and neurology. With an impressive impact factor reflecting its robust contribution to the academic community, EPILEPSIA is categorized in the top quartile (Q1) in both neurology and clinical neurology as of 2023, underscoring its significance and prestige. The journal is ranked #15 out of 192 in Neuroscience & Neurology and #34 out of 400 in Medicine & Neurology (clinical) within Scopus, indicating its essential role in advancing knowledge and treatments related to epilepsy. Researchers and clinicians are encouraged to contribute groundbreaking studies, case reports, and reviews that inform best practices and improve patient outcomes. Although EPILEPSIA currently does not offer open access options, its detailed exploration of both fundamental and clinical aspects of epilepsy ensures wide dissemination of crucial findings among professionals and students alike, furthering the understanding and management of this complex condition.

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

The Cochrane Database of Systematic Reviews is a premier journal published by WILEY, focusing on the critical appraisal and synthesis of high-quality research in health care. With its dedication to evidence-based practice, this journal serves as a cornerstone for researchers, healthcare professionals, and students alike, offering pivotal insights through rigorous systematic reviews. Although it is not an open-access publication, its influence in guiding clinical decision-making and policy formulation is profound, underscored by its contributions to the advancement of healthcare knowledge. Based in the United States at 111 River St, Hoboken, NJ, the Cochrane Database has established itself as essential reading for those seeking to stay at the forefront of systematic reviews and meta-analyses in the medical field, ensuring that users are well-equipped with the evidence necessary for informed practice.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Clinical Obesity, published by WILEY, is a leading journal in the field of Endocrinology, Diabetes, and Metabolism that strives to advance the understanding of obesity-related health issues. With an ISSN of 1758-8103 and an E-ISSN of 1758-8111, this journal provides a platform for cutting-edge research and findings pertaining to the epidemiology, pathophysiology, prevention, and treatment of obesity. Recognized with a Q2 ranking in both Endocrinology, Diabetes and Metabolism and Medicine (miscellaneous) categories, and boasting a Scopus rank of #90 out of 244, Clinical Obesity encompasses innovative studies that influence clinical practice and public health policies. While this journal operates under a subscription model, its discipline-specific contributions are invaluable for researchers, healthcare professionals, and students keen on addressing the complexities of obesity in a comprehensive manner.